Pozen News

News on Pozen (Ticker: POZN) continually updated from thousands of sources around the net.

Thursday May 24 | AmericanBankingNews.com

Roth Capital Analysts Initiate Coverage on POZEN

Other equities research analysts have also recently issued reports about the stock.

Comment?

Sun May 20, 2012

MediLexicon

PA32540 Cuts Gastric Acid Faster Than Enteric-Coated Aspirin

The investigational compound PA32540 provides faster gastric protection than enteric-coated omeprazole 40 mg, researchers announced at Digestive Disease Week 2012.

Comment?

Tue May 08, 2012

BioSpace

Pozen, Inc. Announces Licensing Deal with Desitin Pharmaceuticals...

Pozen, Inc. Announces Licensing Deal with Desitin Pharmaceuticals GmbH for MT 400 Migraine Treatment in 29 European Countries CHAPEL HILL, N.C.-- --POZEN Inc.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Migraine, Health

News Observer

Pozen inks European licensing deal for migraine drug

Chapel Hill drug company Pozen announced Tuesday that it has entered into a licensing agreement to development and commercialize MT 400, its experimental migraine drug, in Europe.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Migraine, Health

Wed May 02, 2012

AmericanBankingNews.com

Pozen PT Raised to $6.00 at Jefferies Group

POZEN opened at 6.83 on Wednesday. POZEN has a 52-week low of $2.15 and a 52-week high of $8.12. The company has a market cap of $204.7 million and a price-to-earnings ratio of 4.88. The company last announced its quarterly results on Tuesday, May 1st.

Comment?

Mon Apr 30, 2012

Local Tech Wire

Pozen runs into a headache with FDA over safer aspirin

Pozen , now prepping to file a new drug application for its safer form of aspirin, has run into a slight regulatory headache.

Comment?